Tessa Romero
Stock Analyst at JP Morgan
(4.27)
# 414
Out of 5,056 analysts
69
Total ratings
48.08%
Success rate
20.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $38.52 | +22.01% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $2.97 | +8,755.22% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $23.65 | +31.08% | 11 | Nov 17, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $20.15 | -15.63% | 7 | Nov 14, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $21.91 | +55.18% | 11 | Nov 14, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $2.60 | - | 5 | Sep 16, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $8.84 | +522.17% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $66.37 | -20.14% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $9.15 | +9.29% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $25.53 | +48.87% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $20.86 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $13.15 | +120.53% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $45.12 | +1.95% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $40.43 | +36.04% | 2 | Apr 25, 2023 |
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $38.52
Upside: +22.01%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $2.97
Upside: +8,755.22%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $23.65
Upside: +31.08%
Dyne Therapeutics
Nov 14, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $20.15
Upside: -15.63%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $21.91
Upside: +55.18%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.60
Upside: -
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $8.84
Upside: +522.17%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $66.37
Upside: -20.14%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $9.15
Upside: +9.29%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $25.53
Upside: +48.87%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $20.86
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $13.15
Upside: +120.53%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $45.12
Upside: +1.95%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $40.43
Upside: +36.04%